Cytovance Biologics Announces New CEO
OKLAHOMA CITY--(BUSINESS WIRE)--Cytovance, a biopharmaceutical contract manufacturing organization (CMO) specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the selection of Atlanta biotech executive Darren Head as Chief Executive Officer.
Mr. Head comes to Cytovance from Atlanta-based Immucor where he served as vice-president of world wide operations, overseeing the manufacturing of biological products in the U.S., Europe and Canada.
“Darren is a very accomplished executive ready to immediately take the helm with 18 years of broad experience in both the scientific and business sides of our industry,” said William Canfield M.D. Ph.D., chairman of Cytovance Biologics. “It is critical for the advancement of Cytovance that the CEO has the vision, practical industry knowledge and experience to ignite and sustain new growth in this business segment. We are confident Darren Head is that executive.”
Before coming to Cytovance, Head was also a vice-president and general manager at Gamma Biologicals/Immucor in Houston. Prior to that, he was an operations manager and project manager for such companies as Aronex Pharmaceuticals, Allergan Optical in Waco, Texas and Abbott Laboratories in North Carolina.
“Cytovance has a diverse and growing client portfolio and is filing a vital gap in biopharmaceutical contract manufacturing services here in the very center of the nation,” noted Head. “I’m impressed with the dedication and integrity this company brings to its clients and the scientific community; the first year plus of operations has built a solid foundation that will be a positive springboard for growth now and in the future.”
Cytovance is currently serving a variety of clients ranging from start-up biotech companies to well established biotech or pharmaceutical companies. Drugs under development for these clients consist of both antibodies and other novel glycoproteins. The stage of development for these drugs ranges from preclinical research to phase II.
About Cytovance Biologics
Cytovance Biologics is a biopharmaceutical contract manufacturing organization (CMO) specializing in the production of therapeutic proteins and antibodies from mammalian cell culture. An experienced management team formed the company to address the biotechnology industry’s increasing needs for full-service manufacturing capacity at the clinical and early commercial scale. In addition to its cGMP manufacturing services, the company offers process development services, cGMP cell banking and regulatory support services from its Oklahoma City, Okla. facilities. For more information on Cytovance, visit www.cytovance.com.
Contacts
For Cytovance Biologics Jane Braden, 405-818-1905